


CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOV, LTD.

12th Floor
Seven Penn Center
1635 Market Street
Philadelphia, PA 19103-2212



Attorney Docket No.: E1067/20011
Customer No. 03000

Date: May 21, 2001

PATENT APPLICATION

AMENDMENT TRANSMITTAL

In re the Application of David J. Brayden

Application No.: 09/386,709
Filed: August 31, 1999

Confirmation No.: Group Art Unit: 1641
Examiner: Jennifer Graser

For: ORAL VACCINE COMPOSITIONS

Attn: Box Fee Amendment
Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAY 25 2001

TECH CENTER 1600/2900

Sir:

■ Transmitted herewith is an Amendment in the above-identified application.

□ A verified statement to establish small entity status under 37 C.F.R. §§1.9 and 1.27 is enclosed.

□ Small entity status of this application under 37 C.F.R. §§1.9 and 1.27 has been established by a verified statement previously submitted.

■ The filing fee has been calculated as shown below:

				SMALL ENTITY			OTHER THAN A SMALL ENTITY	
(Column 1)	(Column 2)	(Column 3)		RAT E	ADD'L FEE	O R	RATE	ADD'L FEE
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA					
TOTAL CLAIMS	* MINUS 27	** 20	= 7	x 9	\$		x 18	\$ 126
INDEP CLAIMS	* MINUS 6	*** 4	= 2	x 40	\$		x 80	\$ 160
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+135	\$		+270	\$ 0
					\$	O R		\$ 286

* If the entry in Column 1 is less than the entry in Column 2, write "0" in Column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" in this space (Total or Independent) is the highest number found from the equivalent box in Column 1 of a prior Amendment or the number of claims originally filed.

The Commissioner is hereby authorized to charge payment of any further filing fees under 37 C.F.R. §1.16 for presentation of extra claims or credit any overpayment to Deposit Account No. 03-0075. A duplicate copy of this sheet is attached if any fees are calculated to be due.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN
COHEN & POKOTILOV, LTD.

By

Robert S. Silver
Reg. No. 35,681

Amat
11/H (10)
PATENT 5/30/01

Attorney Docket No. 99.1081.US (E1067/20011)


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT EXAMINING OPERATION

Applicant : DAVID J. BRAYDEN
Serial No. : 09/386,709
Filed : AUGUST 31, 1999
For : ORAL VACCINE COMPOSITIONS
Group : 1641
Examiner : JENNIFER GRASER

RECEIVED

MAY 25 2001

TECH CENTER 1600/2900



AMENDMENT

Attn: Box Fee Amendment
Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Office Action dated February 5, 2001, please amend the above application as follows:

IN THE CLAIMS:

Please cancel pending method claims 13-20 without prejudice and add the following composition claims:

21. A vaccine formulation for oral administration comprising:
a therapeutically effective amount of a coacervate, the coacervate comprising microparticles of at least one antigen and a biocompatible, biodegradable polymer, wherein the at least one antigen is entrapped or encapsulated by the biocompatible, biodegradable polymer and at least 50% of the microparticles are less than 5 μ m; and

CE/25/2001 NYUSHT 00000001 030075 09386709

CE 75 00 000.00 CH
CE 75 00 000.00 CH